

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christensen, IV, et al.

Serial No.: 10/598,838

Group Art Unit No.: 1625

Filed: 13 September 2006

Examiner: Not Yet Assigned

For: Pyrazolo [3,4-b] Pyridine Compound, and its use as a PDE4 Inhibitor

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FILING OF A SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

/JamesMKanagy/

James M. Kanagy  
Attorney for Applicants  
Registration No. 29,550

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5014  
Facsimile (610) 270-5090

N:\JMK\PATAPPS\PB60771\IDS\_1449\_Jun2007.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60771	APPLICATION NO. 10/598,838
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Christensen, IV, et al.	
		FILING DATE 13 Sept 2006	GROUP 1625

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
NR	US-3,755,340	Aug-73	Hoehn et al.			
NR	US-3,833,594	Sep-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
NR	US-3,833,598	Sep-74	Denzel et al.			
NR	US-3,840,546	Oct-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
NR	US-3,856,799	Dec-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
NR	US 3 925 388 A	Dec-75	Hoehn et al.			
NR	US-3,966,746	Jun-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
NR	US-3,979,399	Sep-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
NR	US-4,115,394	Sep-78	Hoehn, et al.			
NR	US-5,593,997	Jan-97	Dow, Koch and Schulte			
NR	US-2005/0043319	Feb-05	Schweighoffer and Guillet			
NR	US-2006/0089375A1	Apr-06	Allen, et al.			
NR	US-2006/0252790A1	Nov-06	Allen, et al.			
NR	US-2007/0111995A1	May-07	Allen, et al.			
NR	US 10/598973	Mar-05	Cook, et al.			
NR	US 10/598838	Mar-05	Christensen, IV			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
NR		CA-1003419	Jan-77	Canada				
NR		CH-553 799	Sep-74	Switzerland				
	NR	EP-0 076 035	Apr-83	EPC				
	NR	EP-0 180 318	May-86	EPC				
	NR	GB 141 7489	Dec-73	GB				
	NR	GB 151 1006	Apr-75	GB				
	NR	JP-2002-020386	Jan-02	Japan				
	NR	WO-00/15222	Mar-00	PCT				
	NR	WO-01/23389A2	Apr-01	PCT				
	NR	WO-01/44244A1	Jun-01	PCT				
	NR	WO-02/060900	Aug-02	PCT				
	NR	WO-02/081463	Oct-02	PCT				
	NR	WO-02/098878	Dec-02	PCT				
	NR	WO-03/016563	Feb-03	PCT				
	NR	WO-04/056823A1	Jul-04	PCT				
	NR	WO-04/024728A2	Mar-04	PCT				
	NR	WO-2005/058892	Jun-05	PCT				
	NR	WO-2005/090348	Sep-05	PCT				
	NR	WO-2005/090353	Sep-05	PCT				
	NR	WO-2005/090354	Sep-05	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

NR	BARE T.M. ET AL.; Synthesis and structure-activity relationships of a series of anxiolytic pyrazolopyridine ester and amide anxiolytic agents; Journal of Medicinal Chemistry; 1989; 32; pages 2561-2573
NR	BEER B., ET AL.; "Enhancement of 3H-diazepam binding by SQ 65,396: a novel anti-anxiety agent"; Pharmacology Biochemistry & Behaviour; 1978; 9; pp. 849-851
NR	BONDAVALLI F. ET AL.; Synthesis, molecular modelling studies, and pharmacological activity of selective A1 receptor antagonists; Journal of Medicinal Chemistry; 2002; 45(22); pages 4875-4887
NR	CHAKRAVORTI; Synthesis of Some Isoquinolylpyrazolo[3,4-b]pyridine Derivates as Possible Antifilarial Agents; Indian J. Chem.; February 1978; Vol. 16B, pp. 161-163
NR	CHASIN M., ET AL.; "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009) - a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases"; Biochemical Pharmacology; 1972; 21; pp. 2443-2450
NR	CHEMICAL ABSTRACTS REGISTRY – CAS registry number 502143-17-1 which has the laboratory code NSC 235755, 8th April 2003.
NR	DALY J. W. ET AL.; "1-methyl-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pages 293-306; Birkhaeuser; Boston US
NR	DAVIS A., ET AL.; "Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"; Journal of Computer-Aided Molecular Design; 1987; 1; pp. 97-119
NR	DE MELLO, A. ECHEVARRIA, ET AL.; Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis; Journal of Medicinal Chemistry; 2004; 47(22); pages 5427-5432
NR	DENZEL TH.; (translation of title: NEW SYNTHESIS OF 1-UNSUBSTITUTED 1H-PYRAZOLO [3.4-b] PYRIDINE-5-CARBOXYLIC ACID ESTERS); Archiv der Pharmazie; 1974; 307(3); pages 177-186
NR	GIEMBYCZ M.A.; Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?; Drugs; 2000; 59(2); pages 193-212
NR	GLASS II, W. F., ET AL.; "Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors"; Biochemical Pharmacology; 1979; 28; pp. 1107-1112
NR	HOEHN H. ET AL.; 1H-pyrazolo[3,4-b]pyridines; Journal of Heterocyclic Chemistry; 1972; 9(2); pages 235-253
NR	HOHN H ET AL: "Potential Antidiabetic Agents. Pyrazolo6,3,4-b]pyridinesW JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 16, no. 12, 1973, pages 1340-1346, XP002097814 ISSN: 0022-2623 page 1343; compound 37
NR	HOROWITZ Z. P., ET AL.; "Cyclic AMP and anxiety"; Psychosomatics; 1972; vol. XIII, no. 2; pp. 85-92
NR	KRIPALANI K. J. ET AL.; "Biotransformation in the monkey of cartazolate (SQ 65,396), a substituted pyrazolopyridine having anxiolytic activity"; Xenobiotica; 1981; 11(7); pp. 481-488
NR	OCHIAI H. ET AL.; Discovery of new orally active phosphodiesterase (PDE4) inhibitors; Chem. Pharm. Bull.; 2004 (stated to have been published online 15 June 2004); 52(9); pages 1098-1104
NR	OCHIAI H. ET AL.; Bioorg. Med. Chem. Web Release; 2003
NR	OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; Bioorg. Med. Chem.; 2004 (stated to have been available online 20 June 2004); 12(15); pages 4089-4100
NR	OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; Bioorg. Med. Chem. Lett.; 5th Jan 2004 issue (available as "articles in press" version on or before 4th December 2003, possibly October 2003, via internet); 14(1); pages 29-32
NR	PATEL J.B. AND MALICK J.B.; Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent; Eur. J. Pharmacol.; 1982; 78; pages 323-333
NR	PATEL J.B., ET AL.; "Pharmacology of pyrazolopyridines"; Pharmacology Biochemistry & Behaviour; 1985; vol. 23; pp. 675-680

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

<input checked="" type="checkbox"/>	NR	POLSON J. B., ET AL.; "Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle"; Biochemical Pharmacology; 1979; 28; pp. 1391-1395
<input checked="" type="checkbox"/>	NR	RBI 1998, Catalogue no. T-112, Tracazolate"; 1998; page 340
<input checked="" type="checkbox"/>	NR	SABITHA, ET AL.; A Facile Route to Pyrazolo[3,4-b]Pyridines and [1]Benzopyrano[4',3'-e]Pyrazolo[3,4-b]Pyridines; Indian Institute of Chemical Technology; 1999; 29(4),655-665; Synthetic Communications; India
<input checked="" type="checkbox"/>	NR	SCHENONE S. ET AL.; Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands; Bioorg. Med. Chem. Lett.; 2001; 11; pages 2529-2531
<input checked="" type="checkbox"/>	NR	SHI D., ET AL.; Pyrazolopyridines: effect of structural alterations on activity at adenosine- and GABA-A receptors; Drug Development Research; 1997; 42; pages 41-56
<input checked="" type="checkbox"/>	NR	WEINRYB I., ET AL.; "Studies in vitro and in vivo with SQ-20,009: an inhibitor of cyclic nucleoside phosphodiesterase with central nervous system activity"; Excerpta Med. Int. Congr. Ser.; 1975; 359; pp. 857-865
<input checked="" type="checkbox"/>	NR	YU G., MASON H.J., ET. AL.; Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction; Journal of Medicinal Chemistry; 2001; 44; pages 1025-1027
EXAMINER		DATE CONSIDERED
<input checked="" type="checkbox"/> NILOOFAR RAHMANI		<input checked="" type="checkbox"/> 12/17/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		